122.21
-6.23 (-4.85%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 37406.85 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 38.67 | ||
| P/tB | N/A | ||
| EV/EBITDA | -46.74 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -62.49% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | -78625.2% | ||
| PM (TTM) | -79392.91% | ||
| GM | N/A | ||
| FCFM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.14 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 11.1 | ||
| Quick Ratio | 11.1 | ||
| Altman-Z | 71.38 |
ChartMill assigns a fundamental rating of 2 / 10 to EIDX.
ChartMill assigns a valuation rating of 0 / 10 to Eidos Therapeutics Inc (EIDX). This can be considered as Overvalued.
Eidos Therapeutics Inc (EIDX) has a profitability rating of 0 / 10.
The financial health rating of Eidos Therapeutics Inc (EIDX) is 7 / 10.